Provided by Tiger Trade Technology Pte. Ltd.

Verastem

7.55
+0.23003.14%
Post-market: 7.45-0.1000-1.32%19:30 EDT
Volume:1.73M
Turnover:13.30M
Market Cap:683.75M
PE:-3.13
High:7.91
Open:7.58
Low:7.54
Close:7.32
52wk High:10.82
52wk Low:3.43
Shares:90.56M
Float Shares:70.57M
Volume Ratio:0.83
T/O Rate:2.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4143
EPS(LYR):-3.0223
ROE:-471.16%
ROA:-49.59%
PB:13.68
PE(LYR):-2.50

Loading ...

Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375

TIPRANKS
·
Jun 17

Verastem Oncology Doses First Patient in Target-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral Kras G12d (on/off) Inhibitor for Kras G12d-Mutated Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Jun 17

Verastem Oncology updates Phase 1/2 TARGET-D 101 data for KRAS G12D inhibitor VS-7375

Reuters
·
Jun 16

Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM)

TIPRANKS
·
Jun 09

Verastem's Lung Cancer Drug Gets FDA Fast Track Designation

MT Newswires Live
·
Jun 04

BUZZ-Verastem rises after FDA grants fast-track status for cancer drug

Reuters
·
Jun 04

BRIEF-Verastem Initiates Phase 2 Target-D 202 Trial For Advanced NSCLC

Reuters
·
Jun 04

Verastem announces FDA Fast Track designation for VS-7375

TIPRANKS
·
Jun 04

Verastem wins FDA fast-track tag for VS-7375 in KRAS G12D-mutated advanced NSCLC after prior therapy

Reuters
·
Jun 04

Verastem - Initiates Phase 2 Target-D 202 Trial for Advanced Nsclc

THOMSON REUTERS
·
Jun 04

Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational Kras G12d (on/off) Inhibitor for the Treatment of Kras G12d-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Jun 04

Verastem files Form 3 initial beneficial ownership statement for director Michael P. Bailey

Reuters
·
May 28

Verastem Oncology to present at Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 27

H.C. Wainwright Sticks to Their Buy Rating for Verastem (VSTM)

TIPRANKS
·
May 27

Verastum Oncology Appoints Michael P. Bailey to Its Board of Directors

Deep News
·
May 26

Verastem appoints Michael Bailey to board of directors

TIPRANKS
·
May 26

Verastem shareholders approve amended 2021 equity incentive plan at annual meeting

Reuters
·
May 26

Verastem Oncology appoints AVEO CEO Michael P. Bailey to board

Reuters
·
May 26

Verastem Oncology Appoints Michael P. Bailey to Its Board of Directors

THOMSON REUTERS
·
May 26

Verastem (VSTM) Receives a Buy from B. Riley Securities

TIPRANKS
·
May 22